|Bid||0.00 x 800|
|Ask||0.00 x 2200|
|Day's Range||87.83 - 87.93|
|52 Week Range||8.80 - 87.93|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Daniel O'Day has made increasingly larger deals in an effort to improve the company's portfolio of cancer drugs.
Gilead Sciences (NASDAQ: GILD) is a veritable monster in the pharmaceutical industry. Thanks to its industry-leading entry into the coronavirus market this year with its antiviral treatment, remdesivir, Gilead has been a favorite stock for speculative and more critical healthcare investors alike. On the other hand, there are several headwinds that may prevent Gilead's stock from growing as rapidly as its investors might like.
The company's recent acquisition at a lofty premium looks similar to other Gilead deals. That could mean one of two things for investors.